Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 36.36
NVO's Cash to Debt is ranked lower than
51% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. NVO: 36.36 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 11.99 Max: N/A
Current: 36.36
Equity to Asset 0.47
NVO's Equity to Asset is ranked lower than
73% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVO: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.65 Max: 0.73
Current: 0.47
0.42
0.73
F-Score: 5
Z-Score: 11.98
M-Score: -2.62
WACC vs ROIC
11.59%
141.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 43.53
NVO's Operating margin (%) is ranked higher than
96% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. NVO: 43.53 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 32.4 Max: 45.81
Current: 43.53
21.38
45.81
Net-margin (%) 33.74
NVO's Net-margin (%) is ranked higher than
93% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NVO: 33.74 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 24.74 Max: 33.74
Current: 33.74
16.65
33.74
ROE (%) 88.71
NVO's ROE (%) is ranked higher than
99% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. NVO: 88.71 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 22.36  Med: 42.79 Max: 88.71
Current: 88.71
22.36
88.71
ROA (%) 43.09
NVO's ROA (%) is ranked higher than
98% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. NVO: 43.09 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 14.9  Med: 25.96 Max: 43.09
Current: 43.09
14.9
43.09
ROC (Joel Greenblatt) (%) 162.65
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NVO: 162.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.68  Med: 87.94 Max: 178.92
Current: 162.65
36.68
178.92
Revenue Growth (3Y)(%) 14.00
NVO's Revenue Growth (3Y)(%) is ranked higher than
65% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NVO: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.3  Med: 14 Max: 127.9
Current: 14
-46.3
127.9
EBITDA Growth (3Y)(%) 17.60
NVO's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NVO: 17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.4  Med: 16.7 Max: 130.3
Current: 17.6
-44.4
130.3
EPS Growth (3Y)(%) 20.30
NVO's EPS Growth (3Y)(%) is ranked higher than
75% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NVO: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.6  Med: 20.4 Max: 36.9
Current: 20.3
5.6
36.9
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVO's 10-Y Financials

Financials (Next Earnings Date: 2017-02-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVO Guru Trades in Q1 2016

Jeremy Grantham 122,600 sh (New)
Ruane Cunniff 97,525 sh (+19.93%)
Mario Gabelli 6,225 sh (+0.24%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (-0.51%)
Jim Simons 12,775,700 sh (-0.95%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
Q2 2016

NVO Guru Trades in Q2 2016

Jim Simons 12,949,800 sh (+1.36%)
Tom Gayner 1,075,000 sh (unchged)
Spiros Segalas 6,179,837 sh (unchged)
Murray Stahl 7,740 sh (-0.60%)
Mario Gabelli 6,176 sh (-0.79%)
Ken Fisher 10,963,094 sh (-1.93%)
Ruane Cunniff 94,165 sh (-3.45%)
Jeremy Grantham 87,600 sh (-28.55%)
» More
Q3 2016

NVO Guru Trades in Q3 2016

Jim Simons 14,653,500 sh (+13.16%)
Murray Stahl 7,787 sh (+0.61%)
Spiros Segalas 7,212,304 sh (+16.71%)
Ruane Cunniff 94,165 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli Sold Out
Ken Fisher 10,910,669 sh (-0.48%)
Jeremy Grantham 61,700 sh (-29.57%)
» More
Q4 2016

NVO Guru Trades in Q4 2016

Spiros Segalas Sold Out
Ken Fisher 10,621,538 sh (-2.65%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:GILD, NAS:CELG, NAS:AMGN, NAS:BIIB, OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:UCBJY, NAS:GRFS, OTCPK:GMXAY, OTCPK:NVZMY, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:JAZZ » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Novo Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was launched in the United States in April 2015 and is also available in Denmark, Italy and Canada. The Company manufactures and markets pharmaceutical products and services that make a difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes & obesity care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Saudi Arabia, Algeria, Turkey, Argentina, Australia, India, Brazil, Iran and Russia.

Top Ranked Articles about Novo Nordisk A/S

Something Strange Is Going On With Oral Insulin Novo Nordisk recently abandoned program despite promising results
Something is rotten in the state of Denmark. Read more...
The PBM Empire Strikes Back Some of the largest pharmacy benefit managers are driving significant change in drug pricing
I had the privilege of speaking at the GuruFocus Conference in Omaha. The basis of my talk was finding value in health care. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.79
NVO's P/E(ttm) is ranked higher than
70% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. NVO: 16.79 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 23.59 Max: 34.41
Current: 16.79
12.13
34.41
Forward P/E 15.77
NVO's Forward P/E is ranked higher than
56% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 17.86 vs. NVO: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.79
NVO's PE(NRI) is ranked higher than
71% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 28.58 vs. NVO: 16.79 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.13  Med: 23.59 Max: 34.41
Current: 16.79
12.13
34.41
Price/Owner Earnings (ttm) 19.05
NVO's Price/Owner Earnings (ttm) is ranked higher than
61% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. NVO: 19.05 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 27.97 Max: 59.57
Current: 19.05
13.81
59.57
P/B 15.17
NVO's P/B is ranked lower than
91% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. NVO: 15.17 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.68  Med: 8.75 Max: 31.9
Current: 15.17
3.68
31.9
P/S 5.67
NVO's P/S is ranked higher than
68% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. NVO: 5.67 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.86 Max: 11.01
Current: 5.67
2.8
11.01
PFCF 16.34
NVO's PFCF is ranked higher than
66% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. NVO: 16.34 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.52 Max: 47.08
Current: 16.34
12.07
47.08
POCF 13.29
NVO's POCF is ranked higher than
70% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. NVO: 13.29 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.9 Max: 32.54
Current: 13.29
9.91
32.54
EV-to-EBIT 14.45
NVO's EV-to-EBIT is ranked higher than
63% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. NVO: 14.45 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.8 Max: 25.7
Current: 14.45
9.2
25.7
EV-to-EBITDA 13.44
NVO's EV-to-EBITDA is ranked higher than
58% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. NVO: 13.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.1 Max: 23.6
Current: 13.44
8.2
23.6
PEG 0.95
NVO's PEG is ranked higher than
72% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. NVO: 0.95 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.7  Med: 1.19 Max: 5.14
Current: 0.95
0.7
5.14
Shiller P/E 31.98
NVO's Shiller P/E is ranked higher than
70% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 46.84 vs. NVO: 31.98 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 23.23  Med: 43.84 Max: 67.69
Current: 31.98
23.23
67.69
Current Ratio 1.24
NVO's Current Ratio is ranked lower than
84% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NVO: 1.24 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.96 Max: 2.45
Current: 1.24
1.04
2.45
Quick Ratio 0.90
NVO's Quick Ratio is ranked lower than
86% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. NVO: 0.90 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.3 Max: 1.91
Current: 0.9
0.74
1.91
Days Inventory 287.28
NVO's Days Inventory is ranked lower than
83% of the 437 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. NVO: 287.28 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 292.48 Max: 343.56
Current: 287.28
246.45
343.56
Days Sales Outstanding 53.34
NVO's Days Sales Outstanding is ranked higher than
57% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. NVO: 53.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 53.34
45.09
53.6
Days Payable 96.52
NVO's Days Payable is ranked higher than
69% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. NVO: 96.52 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 65.17  Med: 93.12 Max: 124.07
Current: 96.52
65.17
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.97
NVO's Dividend Yield is ranked higher than
91% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. NVO: 3.97 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.93  Med: 1.56 Max: 4.17
Current: 3.97
0.93
4.17
Dividend Payout 0.63
NVO's Dividend Payout is ranked lower than
80% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. NVO: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.26  Med: 0.34 Max: 0.63
Current: 0.63
0.26
0.63
Dividend Growth (3y) 21.30
NVO's Dividend Growth (3y) is ranked higher than
76% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NVO: 21.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 26 Max: 37.5
Current: 21.3
0
37.5
Forward Dividend Yield 3.97
NVO's Forward Dividend Yield is ranked higher than
91% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.41 vs. NVO: 3.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 13.75
NVO's Yield on cost (5-Year) is ranked higher than
97% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.67 vs. NVO: 13.75 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.22  Med: 5.4 Max: 14.44
Current: 13.75
3.22
14.44
3-Year Average Share Buyback Ratio -3.10
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. NVO: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.5 Max: 8
Current: -3.1
-3.1
8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 114.61
NVO's Price/Net Current Asset Value is ranked lower than
98% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. NVO: 114.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 24.72 Max: 696.47
Current: 114.61
11.62
696.47
Price/Tangible Book 16.37
NVO's Price/Tangible Book is ranked lower than
89% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. NVO: 16.37 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 6.9 Max: 31.52
Current: 16.37
3.14
31.52
Price/Projected FCF 1.53
NVO's Price/Projected FCF is ranked higher than
73% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. NVO: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.41  Med: 2.41 Max: 82.77
Current: 1.53
1.41
82.77
Price/DCF (Earnings Based) 0.59
NVO's Price/DCF (Earnings Based) is ranked higher than
80% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NVO: 0.59 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.98
NVO's Price/Median PS Value is ranked lower than
51% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NVO: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.82 Max: 1.78
Current: 0.98
0.13
1.78
Price/Peter Lynch Fair Value 0.85
NVO's Price/Peter Lynch Fair Value is ranked higher than
75% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 1.63 vs. NVO: 0.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.19  Med: 1.04 Max: 3.78
Current: 0.85
0.19
3.78
Price/Graham Number 3.50
NVO's Price/Graham Number is ranked lower than
64% of the 197 Companies
in the Global Biotechnology industry.

( Industry Median: 2.44 vs. NVO: 3.50 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.58  Med: 2.71 Max: 6.75
Current: 3.5
1.58
6.75
Earnings Yield (Greenblatt) (%) 6.90
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. NVO: 6.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 6.9
3.9
10.8
Forward Rate of Return (Yacktman) (%) 24.03
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 15.03 vs. NVO: 24.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 22.7 Max: 33.5
Current: 24.03
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,571
EPS (TTM) $ 2.20
Beta0.61
Short Percentage of Float0.12%
52-Week Range $30.89 - 57.81
Shares Outstanding (Mil)2,600.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 15,731 16,313 17,326
EPS ($) 2.16 2.26 2.35
EPS w/o NRI ($) 2.16 2.26 2.35
EPS Growth Rate
(3Y to 5Y Estimate)
6.75%
Dividends Per Share ($) 0.83 0.91 0.88
» More Articles for NVO

Headlines

Articles On GuruFocus.com
7 Stocks for 2017 Jan 20 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
23 Questions With Thomas Macpherson of Nintai Partners Nov 21 2016 
Graham's 4 Vital Elements Nov 10 2016 
World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 
Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary Oct 26 2016 
Novo Nordisk: Jim Simons' Largest Holding Oct 24 2016 
Stocks With High Yield: Oracle, Cal-Maine, Infosys Jul 28 2016 

More From Other Websites
NOVO NORDISK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Jan 20 2017
7 Stocks for 2017 Jan 20 2017
SHAREHOLDER ALERT: CLASS PERIOD EXPANDED IN CLASS ACTION LAWSUIT – Brower Piven Encourages... Jan 20 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 20 2017
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Novo Nordisk A/S Investors Jan 20 2017
NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action... Jan 17 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 16 2017
NOVO NORDISK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Jan 13 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 13 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S... Jan 13 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo... Jan 12 2017
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who... Jan 12 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Novo Nordisk A/S of a Class Action... Jan 12 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 12 2017
2 MONTHS REMAIN FOR NOVO NORDISK A/S INVESTORS: Hagens Berman Alerts Novo Nordisk Investors to... Jan 12 2017
Drug makers, auto stocks yank European stocks lower for first time in 3 days Jan 12 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 12 2017
Novo Nordisk shares hit by U.S. lawsuit, Trump comments Jan 12 2017
Novo Nordisk slumps 5.4% on U.S. price fixing lawsuit Jan 12 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)